What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2024-02-27 compared with 2023-03-01 · 95 added, 85 removed, 190 unchanged (49% of the section changed)

1 unchanged sentence

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of January 1, 2023.

The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023.

processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures as of January 1, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Report on Internal Control Over Financial Reporting

6 unchanged sentences

Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of January 1, 2023.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023.

In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013) .

Based on this assessment, our management concluded that, as of January 1, 2023, our internal control over financial reporting was effective based on those criteria.

Based on this assessment, our management concluded that, as of December 31, 2023, our internal control over financial reporting was effective based on those criteria.

Our registered public accounting firm has issued an attestation report on our internal control over financial reporting.

1 unchanged sentence

Changes in Internal Control Over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended January 1, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We have not experienced any material impact to our internal controls over financial reporting despite the fact that many of our employees are working remotely due to the COVID-19 pandemic.

We are continually monitoring and assessing the effect of the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of PerkinElmer, Inc.

To the Stockholders and the Board of Directors of Revvity, Inc.

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of PerkinElmer, Inc.

and sub sidiaries (the “Company”) as of January 1, 2023, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 1, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended January 1, 2023 of the Company and our report dated March 1, 2023 expressed an unqualified opinion on those financial statements.

We have audited the internal control over financial reporting of Revvity, Inc.

and subsidiaries (the “Company”) as of December 31, 2023, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2023, of the Company and our report dated February 27, 2024, expressed an unqualified opinion on those financial statements.

Basis for Opinion

13 unchanged sentences

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.

/s / DELOITTE & TOUCHE LLP

Boston, Massachusetts

March 1, 2023

February 27, 2024

Other Information

Not applicable.

Rule 10b5-1 Trading Plans

During the three months ended December 31, 2023 , none of our directors or officers adopted a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as the terms are defined in Item 408(a) of Regulation S-K.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

5 unchanged sentences

We have adopted a code of ethics, our Standards of Business Conduct, that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions.

Our Standards of Business Conduct, as well as our corporate governance guidelines and the charters for the audit, compensation and benefits, nominating and corporate governance, executive and finance committees of our Board of Directors, are each accessible under the “Corporate Governance” heading of the “Investors” section of our website, http://www.perkinelmer.com.

This information is also available in print to any stockholder who requests it, by writing to PerkinElmer, Inc., 940 Winter Street, Waltham, Massachusetts 02451, Attention:

This information is also available in print to any stockholder who requests it, by writing to Revvity, Inc., 940 Winter Street, Waltham, Massachusetts 02451, Attention:

Investor Relations.

15 unchanged sentences

Report of Independent Registered Public Accounting Firm

Consolidated Statements of Operations for Each of the Three Fiscal Years in the Period Ended January 1, 2023

Consolidated Statements of Comprehensive Income for Each of the Three Fiscal Years in the Period Ended January 1, 2023

Consolidated Balance Sheets as of January 1, 2023 and January 2, 2022

Consolidated Statements of Stockholders’ Equity for Each of the Three Fiscal Years in the Period Ended January 1, 2023

Consolidated Statements of Cash Flows for Each of the Three Fiscal Years in the Period Ended January 1, 2023

Consolidated Statements of Operations for Each of the Three Fiscal Years in the Period Ended December 31, 2023

Consolidated Statements of Comprehensive Income for Each of the Three Fiscal Years in the Period Ended December 31, 2023

Consolidated Balance Sheets as of December 31, 2023 and January 1, 2023

Consolidated Statements of Stockholders’ Equity for Each of the Three Fiscal Years in the Period Ended December 31, 2023

Consolidated Statements of Cash Flows for Each of the Three Fiscal Years in the Period Ended December 31, 2023

Notes to Consolidated Financial Statements

2 unchanged sentences

Exhibit Title

Agreement and Plan of Merger, dated as of July 25, 2021, by and among PerkinElmer, Inc., Burton Acquisition I, Inc., Burton Acquisition II, Inc., BioLegend, Inc.

Agreement and Plan of Merger, dated as of July 25, 2021, by and among Revvity , Inc., Burton Acquisition I, Inc., Burton Acquisition II, Inc., BioLegend, Inc.

and Gene Lay, solely in his capacity as the Stockholder Representative, filed with the Commission on July 27, 2021 as Exhibit 2.1 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

Master Purchase and Sale Agreement, dated as of August 1, 2022, by and between PerkinElmer, Inc.

and Polaris Purchaser, L.P., filed with the Commission on August 5, 2022 as Exhibit 2.1 to our current report on Form 8-K (File No.

Amended and Restated Master Purchase and Sale Agreement, dated as of March 11, 2023, by and between PerkinElmer, Inc., PerkinElmer U.S.

LLC and PerkinElmer Topco, L.P.

, filed with the Commission on March 16, 2023 as Exhibit 2.1 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

3.1 PerkinElmer, Inc.'s Restated Articles of Organization, filed with the Commission on May 11, 2007 as Exhibit 3.1 to our quarterly report on Form 10-Q (File No.

3.1 Revvity, Inc.'s Restated Articles of Organization, filed with the Commission on May 12, 2023 as Exhibit 3.1 to our quarterly report on Form 10-Q (File No.

001-05075) and herein incorporated by reference.

3.2 PerkinElmer, Inc.'s Amended and Restated By-laws, filed with the Commission on December 13, 2018 as Exhibit 3.2 to our current report on Form 8-K (File No.

3.2 Revvity, Inc.'s Amended and Restated By-laws, filed with the Commission on May 12, 2023 as Exhibit 3.2 to our quarterly report on Form 10-Q (File No.

001-05075) and herein incorporated by reference.

4.1 Specimen Certificate of PerkinElmer, Inc.'s Common Stock, $1 par value, filed with the Commission on August 15, 2001 as Exhibit 4.1 to our quarterly report on Form 10-Q (File No.

4.1 Specimen Certificate of Revvity , Inc.'s Common Stock, $1 par value, filed with the Commission on August 15, 2001 as Exhibit 4.1 to our quarterly report on Form 10-Q (File No.

001-05075) and herein incorporated by reference.

4.2 Description of PerkinElmer, Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, filed with the Commission on March 3, 2022 as Exhibit 4.2 to our annual report on Form 10-K (File No.

4.2 Description of Revvity , Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, filed with the Commission on March 3, 2022 as Exhibit 4.2 to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

4.3 Indenture dated as of October 25, 2011 between PerkinElmer, Inc.

4.3 Indenture dated as of October 25, 2011 between Revvity , Inc.

Bank National Association, filed with the Commission on October 27, 2011 as Exhibit 99.1 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

4.4 Third Supplemental Indenture, dated as of July 19, 2016, among PerkinElmer, Inc., U.S.

4.4 Third Supplemental Indenture, dated as of July 19, 2016, among Revvity , Inc., U.S.

Bank National Association, as trustee, and Elavon Financial Services DAC, UK Branch, as paying agent, filed with the Commission on July 19, 2016 as Exhibit 4.2 to our current report on Form 8-K (File No.

1 unchanged sentence

Exhibit Title

4.5 Paying Agency Agreement, dated July 19, 2016, among PerkinElmer, Inc., U.S.

4.5 Paying Agency Agreement, dated July 19, 2016, among Revvity , Inc., U.S.

Bank National Association, as trustee, Elavon Financial Services DAC, UK Branch, as paying agent, and Elavon Financial Services DAC, as transfer agent and registrar, filed with the Commission on July 19, 2016 as Exhibit 4.3 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

4.6 Fifth Supplemental Indenture, dated as of September 12, 2019, by and between PerkinElmer, Inc.

4.6 Fifth Supplemental Indenture, dated as of September 12, 2019, by and between Revvity , Inc.

Bank National Association, as trustee (including the form of note contained therein) filed with the Commission on September 12, 2019 as Exhibit 4.2 to our current report on Form 8-K (File No.

6 unchanged sentences

001-05075)) and herein incorporated by reference.

10.1 Credit Agreement, dated as of August 24, 2021, among PerkinElmer, Inc., PerkinElmer Health Sciences, Inc., PerkinElmer Life Sciences International Holdings, PerkinElmer Global Holdings S.à r.l.

and PerkinElmer Health Sciences B.V.

10.1 Credit Agreement, dated as of August 24, 2021, among Revvity, Inc., Revvity Health Sciences, Inc., Revvity Life Sciences International Holdings, Revvity Global Holdings S.à r.l.

and Revvity Health Sciences B.V.

as Borrowers, Bank of America, N.A.

1 unchanged sentence

001-05075) and herein incorporated by reference.

10.2 First Amendment to Credit Agreement, dated as of April 24, 2023, among Revvity, Inc., Revvity Health Sciences, Inc., Revvity Life Sciences International Holdings, Revvity Global Holdings S.à r.l.

and Revvity Health Sciences B.V.

as Borrowers, Bank of America, N.A.

as Administrative Agent, Swing Line Lender and an L/C Issuer, the Lenders party thereto and the other L/C Issuers party thereto, filed with the Commission on August 9, 2023 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No.

001-05075) and herein incorporated by reference.

10.3* Employment Contracts:

(1) Amended and Restated Employment Agreement, dated as of August 21, 2019, between Dr.

Singh and PerkinElmer, Inc., filed with the Commission on August 21, 2019 as Exhibit 99.1 to our current report on Form 8-K (File No.

Singh and Revvity , Inc., filed with the Commission on August 21, 2019 as Exhibit 99.1 to our current report on Form 8-K (File No.

001-05075) and incorporated herein by reference.

(2) Employment Agreement between Joel S.

Goldberg and PerkinElmer, Inc.

Goldberg and Revvity , Inc.

dated as of July 21, 2008, filed with the Commission on August 8, 2008 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No.

1 unchanged sentence

(3) Form of Amendment between Joel S.

Goldberg and PerkinElmer, Inc.

Goldberg and Revvity , Inc.

dated as of December 3, 2010, filed with the Commission on March 1, 2011 as Exhibit 10.4(7) to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

(4) Amended and Restated Employment Agreement between Andrew Okun and PerkinElmer, Inc.

dated as of January 1, 2014, filed with the Commission on February 25, 2014 as Exhibit 10.2(10) to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

(4) Employment Agreement between Daniel R.

Tereau and PerkinElmer, Inc.

Tereau and Revvity, Inc.

dated as of February 1, 2016, filed with the Commission on March 1, 2016 as Exhibit 10.2(8) to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

(6) Employment Agreement between Tajinder Vohra and PerkinElmer, Inc.

(5) Employment Agreement between Tajinder Vohra and Revvity, Inc.

dated as of January 29, 2018, filed with the Commission on May 8, 2018 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No.

001-05075) and herein incorporated by reference.

(7) Employment Agreement between James Mock and PerkinElmer, Inc., dated as of April 10, 2018, filed with the Commission on April 13, 2018 as Exhibit 99.1 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

(8) Employment Agreement between Miriame Victor and PerkinElmer, Inc.

(6) Employment Agreement between Miriame Victor and Revvity, Inc.

dated as of January 1, 2022, filed with the Commission on March 3, 2022 as Exhibit 10.3(8) to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

(9) Employment Agreement between Maxwell Krakowiak and PerkinElmer, Inc.

(7) Employment Agreement between Maxwell Krakowiak and Revvity, Inc.

dated as of August 16, 2022, filed with the Commission on August 17, 2022 as Exhibit 99.1 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

10.3* PerkinElmer, Inc.'s 2009 Incentive Plan, filed with the Commission on March 12, 2014 as Appendix A to our definitive proxy statement on Schedule 14A (File No.

001-05075) and herein incorporated by reference.

10.4* PerkinElmer, Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on December 12, 2008 as Exhibit 10.1 to our current report on Form 8-K (File No.

10.4* Revvity , Inc.'s 2009 Incentive Plan, filed with the Commission on March 12, 2014 as Appendix A to our definitive proxy statement on Schedule 14A (File No.

001-05075) and herein incorporated by reference.

Exhibit Title

10.5* First Amendment to PerkinElmer, Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on March 1, 2011 as Exhibit 10.9 to our annual report on Form 10-K (File No.

10.5* Revvity , Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on December 12, 2008 as Exhibit 10.1 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

10.6* Second Amendment to PerkinElmer, Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on May 10, 20 22 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No.

10.6* First Amendment to Revvity , Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on March 1, 2011 as Exhibit 10.9 to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

10.7* PerkinElmer, Inc.

10.7* Second Amendment to Revvity , Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on May 10, 2022 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No.

001-05075) and herein incorporated by reference.

10.8* Revvity , Inc.

1998 Employee Stock Purchase Plan as Amended and Restated on December 10, 2009, filed with the Commission on March 1, 2010 as Exhibit 10.15 to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

10.8* Form of Stock Option Agreement given by PerkinElmer, Inc.

10.9* Form of Stock Option Agreement given by Revvity , Inc.

to its executive officers for use under the 2009 Incentive Plan, filed with the Commission on April 28, 2009 as Exhibit 10.3 to our current report on Form 8-K (File No.

001-05075) and herein incorporated by reference.

10.9* PerkinElmer, Inc.

10.10* Revvity , Inc.

Savings Plan Amended and Restated effective January 1, 2021, filed with the Commission on March 2, 2021 as Exhibit 10.16 to our annual report on Form 10-K (File No.

001-05075) and herein incorporated by reference.

10.10* PerkinElmer, Inc.

10.11* Revvity , Inc.

Employees Retirement Plan Amended and Restated effective January 1, 2012, as further amended, filed with the Commission on February 26, 2019 as Exhibit 10.26 to our annual report on Form 10-K (file No.

001-05075) and herein incorporated by reference.

10.11* PerkinElmer, Inc.

Amended and Restated Global Incentive Compensation Plan (Executive Officers) effective January 4, 2021, filed with the Commission on May 11, 2021 as Exhibit 10.5 to our quarterly report on Form 10-Q (file No.

001-05075) and herein incorporated by reference.

10.12* PerkinElmer, Inc.'s 2019 Incentive Plan, filed with the Commission on March 13, 2019 as Appendix B to our definitive proxy statement on Schedule 14A (File No.

10.12* Revvity, Inc.

Amended and Restated Global Incentive Compensation Plan (Executive Officers) effective October 2 , 202 3 , attached hereto as Exhibit 10.

10.13* Revvity , Inc.'s 2019 Incentive Plan, filed with the Commission on March 13, 2019 as Appendix B to our definitive proxy statement on Schedule 14A (File No.

001-05075) and herein incorporated by reference.

26 unchanged sentences

001-05075) and herein incorporated by reference.

21 Subsidiaries of PerkinElmer, Inc., attached hereto as Exhibit 21.

10.27* Form of Stock Option Agreement with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.2 7 .

10.28* Form of Stock Option Agreement with double-trigger vesting acceleration following a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.2 8 .

10.29* Form of Restricted Stock Unit Agreement (Performance-based vesting) with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.

10.30* Form of Restricted Stock Unit Agreement (Performance-based vesting) with double -trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.

10.31* Form of Restricted Stock Unit Agreement (Time-based vesting) with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.

10.32* Form of Restricted Stock Unit Agreement (Time-based vesting) with double -trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.

21 Subsidiaries of Revvity, Inc., attached hereto as Exhibit 21.

23 Consent of Independent Registered Public Accounting Firm, attached hereto as Exhibit 23.

3 unchanged sentences

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, attached hereto as Exhibit 32.1.

97* Revvity, Inc.

Dodd-Frank Compensation Recovery Policy effective October 2, 2023, attached hereto as Exhibit 97.

101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

4 unchanged sentences

101.PRE Inline XBRL Presentation Linkbase Document.

Exhibit Title

104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

4 unchanged sentences

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language):

(i) Consolidated Statements of Operations for each of the three years in the period ended January 1, 2023, (ii) Consolidated Balance Sheets as of January 1, 2023 and January 2, 2022, (iii) Consolidated Statements of Comprehensive Income for each of the three years in the period ended January 1, 2023, (iv) Consolidated Statements of Stockholders' Equity for each of the three years in the period ended January 1, 2023, (v) Consolidated Statements of Cash Flows for each of the three years in the period ended January 1, 2023, and (vi) Notes to Consolidated Financial Statements.

(i) Consolidated Statements of Operations for each of the three years in the period ended December 31, 2023, (ii) Consolidated Balance Sheets as of December 31, 2023 and January 1, 2023, (iii) Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2023, (iv) Consolidated Statements of Stockholders' Equity for each of the three years in the period ended December 31, 2023, (v) Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2023, and (vi) Notes to Consolidated Financial Statements.

Form 10-K Summary

1 unchanged sentence

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Signature PERKINELMER, INC.

/s/ P RAHLAD S INGH, PhD

President and Chief Executive Officer March 1, 2023

Signature Title Date

/s/ PRAHLAD SINGH, PhD President and Chief Executive Officer February 27, 2024

Prahlad Singh, PhD

(Principal Executive Officer)

/ S / M AXWELL K RAKOWIAK

Vice President and March 1, 2023

/s/ MAXWELL KRAKOWIAK Sr.

Vice President and Chief Financial Officer February 27, 2024

Maxwell Krakowiak

Chief Financial Officer

(Principal Financial Officer)

/ S / A NDREW O KUN

Vice President, March 1, 2023

Chief Accounting Officer and Treasurer

/s/ ANITA GONZALES Vice President and Controller February 27, 2024

Anita Gonzales

(Principal Accounting Officer)

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of PerkinElmer, Inc., hereby severally constitute Prahlad Singh and Maxwell Krakowiak, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names, in the capacities indicated below, this Annual Report on Form 10-K and any and all amendments to said Annual Report on Form 10-K, and generally to do all such things in our name and behalf in our capacities as officers and directors to enable PerkinElmer, Inc.

We, the undersigned officers and directors of Revvity, Inc., hereby severally constitute Prahlad Singh and Maxwell Krakowiak, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names, in the capacities indicated below, this Annual Report on Form 10-K and any and all amendments to said Annual Report on Form 10-K, and generally to do all such things in our name and behalf in our capacities as officers and directors to enable Revvity, Inc.

to comply with the provisions of the Securities Exchange Act of 1934, and all requirements of the Securities and Exchange Commission, hereby rectifying and confirming signed by our said attorneys, and any and all amendments thereto.

1 unchanged sentence

Signature Title Date

/s/ PRAHLAD SINGH, PhD President, Chief Executive Officer and March 1, 2023

/s/ PRAHLAD SINGH, PhD President, Chief Executive Officer and February 27, 2024

Prahlad Singh, PhD

1 unchanged sentence

/s/ MAXWELL KRAKOWIAK Sr.

Vice President and March 1, 2023

Vice President and February 27, 2024

Maxwell Krakowiak

1 unchanged sentence

(Principal Financial Officer)

/s/ ANDREW OKUN Vice President, Chief Accounting Officer March 1, 2023

and Treasurer

/s/ ANITA GONZALES Vice President and Controller February 27, 2024

Anita Gonzales

(Principal Accounting Officer)

/s/ PETER BARRETT, PhD Director March 1, 2023

/s/ PETER BARRETT, PhD Director February 27, 2024

Peter Barrett, PhD

/s/ SAMUEL R.

CHAPIN Director March 1, 2023

/s/ SYLVIE GRÉGOIRE, PharmD Director March 1, 2023

CHAPIN Director February 27, 2024

/s/ SYLVIE GRÉGOIRE, PharmD Director February 27, 2024

Sylvie Grégoire, PharmD

/s/MICHELLE MCMURRY-HEATH, MD PhD Director March 1, 2023

/s/ MICHAEL A.

KLOBUCHAR Director February 27, 2024

/s/ MICHELLE MCMURRY-HEATH, MD PhD Director February 27, 2024

Michelle McMurry-Heath, MD PhD

/s/ ALEXIS P.

MICHAS Director March 1, 2023

/s MICHEL VOUNATSOS Director March 1, 2023

MICHAS Director February 27, 2024

VANDEBROEK, PhD Director February 27, 2024

Vandebroek, PhD

/s/ MICHEL VOUNATSOS Director February 27, 2024

Michel Vounatsos

/s/ FRANK WITNEY, PhD Director March 1, 2023

/s/ FRANK WITNEY, PhD Director February 27, 2024

Frank Witney, PhD

/s/ PASCALE WITZ Director March 1, 2023

/s/ PASCALE WITZ Director February 27, 2024

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 9A. Controls and Procedures